Companies
OBiO Technology
Shanghai cell-and-gene-therapy CRO/CDMO (SSE STAR Market 688238) packaging plasmid, AAV, lentiviral and adenoviral vectors from research grade through GMP Phase I-III to commercial supply, alongside cell-processing and regenerative-medicine services.
- Country
- China
- Ticker
- SSE STAR: 688238
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | 2013 | obiosh.com |
| Headquarters | Shanghai, China | obiosh.com |
| Funding | Listed on the SSE STAR Market, stock code 688238 | q.stock.sohu.com |
| Regulatory approval | Holds the drug manufacturing licence (Category C); reported a fully commercial closed loop in July 2026 | obiosh.com |
| Capacity | GMP production spanning Phase I/II/III to commercial stage for plasmid, AAV, adenovirus and other viral vectors | obiosh.com |
Independent sources: q.stock.sohu.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Adenoviral vector gene therapy | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.